Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.63
Dollar change
-0.15
Percentage change
-5.40
%
Index- P/E- EPS (ttm)-0.45 Insider Own- Shs Outstand5.69M Perf Week2.73%
Market Cap14.99M Forward P/E- EPS next Y- Insider Trans- Shs Float3.25M Perf Month49.43%
Income-2.57M PEG- EPS next Q- Inst Own0.12% Short Float1.58% Perf Quarter36.27%
Sales2.36M P/S6.35 EPS this Y- Inst Trans- Short Ratio0.05 Perf Half Y31.50%
Book/sh2.10 P/B1.25 EPS next Y- ROA-17.61% Short Interest0.05M Perf Year39.16%
Cash/sh1.96 P/C1.34 EPS next 5Y- ROE-19.52% 52W Range1.48 - 5.96 Perf YTD40.27%
Dividend Est.- P/FCF- EPS past 5Y8.90% ROI-21.37% 52W High-55.87% Beta-
Dividend TTM- Quick Ratio7.79 Sales past 5Y90.79% Gross Margin68.86% 52W Low77.58% ATR (14)0.32
Dividend Ex-Date- Current Ratio8.52 EPS Y/Y TTM-24.14% Oper. Margin-177.70% RSI (14)52.80 Volatility5.76% 14.13%
Employees- Debt/Eq0.01 Sales Y/Y TTM204.79% Profit Margin-108.99% Recom1.00 Target Price207.14
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q-2.11% Payout- Rel Volume0.03 Prev Close2.78
Sales Surprise- EPS Surprise- Sales Q/Q293.15% Earnings- Avg Volume1.03M Price2.63
SMA20-0.61% SMA5021.99% SMA20032.86% Trades Volume29,088 Change-5.40%
Mar-07-24 06:00AM
Feb-21-24 06:00AM
Feb-13-24 06:00AM
Feb-08-24 06:00AM
Jan-16-24 06:00AM
06:00AM Loading…
Dec-22-23 06:00AM
Dec-04-23 06:00AM
Nov-28-23 06:33AM
Nov-13-23 06:00PM
Oct-30-23 07:21AM
Oct-18-23 06:00AM
Oct-11-23 06:00AM
Sep-18-23 07:30AM
Sep-14-23 01:30PM
Sep-13-23 06:00AM
06:00AM Loading…
Sep-11-23 06:00AM
Aug-23-23 08:30AM
Aug-14-23 06:00AM
Jul-26-23 02:45PM
Jul-25-23 06:00AM
Jul-24-23 06:00AM
Jul-19-23 08:30AM
Jul-11-23 06:00AM
Jul-05-23 06:00AM
Jun-30-23 06:00AM
Jun-22-23 06:00AM
May-30-23 06:00AM
May-16-23 07:30AM
May-08-23 01:11PM
06:00AM
06:00AM Loading…
May-02-23 06:00AM
Apr-19-23 06:00AM
Apr-11-23 06:00AM
Apr-06-23 06:00AM
Feb-15-23 06:00AM
Jan-25-23 06:00AM
Jan-18-23 05:00AM
Jan-17-23 07:10AM
Dec-23-22 06:00AM
Dec-05-22 06:00AM
Nov-16-22 07:00AM
Oct-26-22 06:00AM
Oct-13-22 10:28AM
06:00AM
Oct-04-22 06:00AM
Aug-29-22 07:00AM
Aug-19-22 07:23AM
06:00AM
Jul-26-22 07:07AM
06:00AM
Jul-11-22 06:00AM
Jul-07-22 06:00AM
May-11-22 06:00AM
May-09-22 06:00AM
May-05-22 08:22PM
Apr-27-22 06:00AM
Apr-19-22 07:33AM
Mar-25-22 05:21AM
Mar-16-22 09:30AM
Jan-17-22 06:00AM
Jan-13-22 06:00AM
Jan-12-22 02:58PM
07:28AM
06:34AM
06:00AM
04:59AM
Nov-15-21 06:00AM
Nov-10-21 06:00AM
Oct-08-21 08:10AM
07:34AM
06:00AM
Sep-24-21 08:40PM
Sep-23-21 11:00PM
09:00AM
May-13-21 06:00AM
Mar-02-21 11:40AM
Jan-11-21 06:00AM
Dec-15-20 06:00AM
Nov-24-20 06:00AM
Nov-11-20 06:00AM
Oct-12-20 06:00AM
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.